Pharmasaga (PS) devotes itself to developing firs-in-class anti-diabetic drugs. PS has identified Pdia4 as a key molecular target of diabetes and islet failure and, consequently, developed Pdia4 inhibitors that can reverse diabetes. The drugs were approved for IND by USFDA. PS will join BIO 2022 for fundraising and patent out-licensing.

https://livetour.istaging.com/?group=7f9af768-4059-411e-9c4a-ac00d67271ab&pilot=0pn2xC1qABYl7B7e4cig&index=2